$LLY (+1,78 %)
$NVO (-18,32 %)
$HIMS (-1,68 %) | ELI LILLY LAUNCHES SINGLE-DOSE VIALS OF ZEPBOUND FOR WEIGHT LOSS IN U.S.

Eli Lilly has introduced single-dose vials of its weight-loss drug Zepbound in the U.S., offering 2.5 mg and 5 mg doses at $399 and $549 per month, respectively, via LillyDirect. 

This move aims to increase supply amid high demand and address insurance coverage gaps.

Despite the new availability, Zepbound remains on the FDA shortage list. The vials are priced 50% lower than other GLP-1 obesity drugs, targeting patients who can't get reimbursement.